Format

Send to

Choose Destination
Cancer Biomark. 2018;21(4):875-881. doi: 10.3233/CBM-170817.

Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.

Wang D1,2,1, Zhou J3,1, Zheng J3,1, Zhang J2, Chen Y2, Li W1, Wang R2.

Author information

1
Laboratory of Department of General Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
2
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China.
3
Department of Oncology, General Hospital of Guangzhou Military Command of PLA, Guangzhou 510010, Guangdong, China.

Abstract

BACKGROUND:

Cisplatin-based concurrent chemoradiotherapy is recommended for nasopharyngeal carcinoma (NPC) at advanced stages. Excision repair cross-complementation group 1 (ERCC1) plays an important function in the repair of DNA damage that is a critical process of chemo- and radiotherapy.

OBJECTIVE:

This study aimed to investigate the clinical significance of ERCC1 expression in NPC treated with cisplatin-based concurrent chemoradiotherapy in locoregionally advanced NPC.

METHODS:

The expression level of ERCC1 and its association with clinicopathological characteristics in 205 locoregionally advanced NPC patients receiving cisplatin-based concurrent chemoradiotherapy were analyzed retrospectively.

RESULTS:

The correlation analysis revealed that the treatment-sensitive patients displayed dramatically lower ERCC1 expression than treatment-resistant cases did. Furthermore, the Kaplan-Meier plots revealed lower ERCC1 expression was significantly associated with better survival. Multivariate analysis further showed that the ERCC1 expression was an independent predictor of NPC patients' survival.

CONCLUSIONS:

ERCC1 expression might be a useful predictive marker in patients with locoregionally advanced NPC receiving cisplatin-based concurrent chemoradiotherapy.

KEYWORDS:

ERCC1; cisplatin-based concurrent chemoradiotherapy; nasopharyngeal cancer; survival

PMID:
29439312
DOI:
10.3233/CBM-170817
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center